Wegovy Cost in Missouri (2026): Prices, Insurance, and Savings Options

What Does Wegovy Actually Cost in Missouri?

Wegovy's wholesale acquisition cost (WAC) set by Novo Nordisk is $1,349 per month, and Missouri retail pharmacies mirror this figure for cash-pay patients. That number has remained flat since the drug's 2021 FDA approval for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity [1].

Retail Pharmacy Pricing

Cash-pay quotes from major Missouri chains (CVS, Walgreens, Walmart) cluster tightly around the $1,349 WAC. Unlike many generics, there is no meaningful price variation between St. Louis, Kansas City, Springfield, or rural Missouri pharmacies for brand-name Wegovy. The price reflects a single-manufacturer market with no biosimilar competition as of mid-2026.

Why the Price Stays High

Semaglutide 2.4 mg is protected by Novo Nordisk's patent portfolio, which extends into the late 2030s for several formulation and device patents. No FDA-approved generic or biosimilar semaglutide injection exists yet. The SELECT cardiovascular outcomes trial (N=17,604) demonstrated a 20% reduction in major adverse cardiovascular events, which earned Wegovy a supplemental FDA indication for CV risk reduction in March 2024. That expanded label increased demand without adding price competition.

Missouri Medicaid: No Coverage for Weight Management

Missouri Medicaid (MO HealthNet) does not cover Wegovy for chronic weight management. Coverage is restricted to semaglutide at lower doses (Ozempic 0.5 mg, 1 mg, or 2 mg) for the treatment of type 2 diabetes. This policy aligns with the majority of state Medicaid programs. A 2024 KFF analysis found that only 15 states offered any Medicaid coverage for anti-obesity medications [2].

What MO HealthNet Does Cover

For Missouri Medicaid enrollees with type 2 diabetes and obesity, Ozempic (semaglutide 0.25 mg to 2 mg) may be covered through the preferred drug list. The clinical distinction matters: Wegovy's 2.4 mg dose was specifically studied for weight loss in the STEP-1 trial, where participants without diabetes lost a mean of 14.9% of body weight at 68 weeks versus 2.4% with placebo (N=1,961) [1]. Ozempic's maximum 2 mg dose, while sometimes prescribed off-label for weight loss, was studied at different doses in the SUSTAIN program for glycemic control.

Appealing a Medicaid Denial

Patients who believe they have a clinical case for coverage can file a prior authorization appeal through MO HealthNet. Success rates for anti-obesity medications remain low in Missouri. Documentation of failed lifestyle interventions, BMI history, and weight-related comorbidities such as obstructive sleep apnea or osteoarthritis strengthens the appeal, though approval is not guaranteed.

Commercial Insurance Coverage in Missouri

Commercial plan coverage for Wegovy varies considerably across Missouri insurers. Large employers with self-funded plans make independent formulary decisions, which means two patients at the same company in Kansas City and St. Louis could have different coverage depending on their plan tier.

Plans That Commonly Cover Wegovy

Blue Cross Blue Shield of Kansas City, UnitedHealthcare, and Aetna have included Wegovy on select commercial formularies, typically with prior authorization requirements. The standard criteria mirror FDA labeling: BMI ≥30, or BMI ≥27 with at least one comorbidity (hypertension, type 2 diabetes, dyslipidemia). Most plans require documentation of a 6-month supervised diet and exercise program before approval.

Typical Out-of-Pocket With Insurance

For commercially insured patients whose plan covers Wegovy, copays range from $25 to $150 per month depending on formulary tier placement. Specialty tier placement (Tier 4 or 5) triggers coinsurance of 25% to 40%, which can mean $300 to $500 monthly even with coverage. The Endocrine Society's 2024 clinical practice guideline on pharmacologic management of obesity recommends that clinicians help patients explore all available coverage pathways before initiating therapy.

Prior Authorization Tips

Document the patient's complete weight history, prior interventions, and comorbid conditions. Include lab values such as HbA1c for prediabetes screening (ADA threshold: 5.7% to 6.4%) and lipid panels. Attach records from any structured weight management program. A clear letter of medical necessity from the prescribing physician significantly improves approval rates.

The Novo Nordisk Savings Card

Novo Nordisk offers a manufacturer savings program for commercially insured patients. Eligible patients with commercial insurance that covers Wegovy may pay as little as $0 per 28-day supply for up to 13 fills.

Eligibility Requirements

The savings card is available to patients with commercial (private) insurance. It excludes Medicare, Medicaid, TRICARE, and other government-funded programs. Patients must have a valid prescription and insurance that includes Wegovy on its formulary. The card does not apply to cash-pay purchases. Savings amounts vary by plan, but the card can offset copays of up to $225 per fill.

How to Activate

Patients can enroll online or by calling Novo Nordisk's support line. The pharmacy processes the savings card as a secondary claim after the primary insurance adjudicates. Processing takes an additional 2 to 5 minutes at the pharmacy counter. Missouri pharmacies at CVS, Walgreens, and independent locations all accept the card.

Compounded Semaglutide 2.4 mg in Missouri

Licensed 503A compounding pharmacies in Missouri can legally prepare semaglutide 2.4 mg injections when a patient-specific prescription exists. The average cost runs approximately $199 per month, roughly 85% less than brand-name Wegovy.

Legal Status in Missouri

Missouri follows federal law under the Federal Food, Drug, and Cosmetic Act Section 503A, which permits state-licensed pharmacies to compound medications based on individual prescriptions. The Missouri Board of Pharmacy oversees these facilities. Compounded semaglutide is not FDA-approved, and the FDA has issued safety communications warning that compounded versions have not undergone the same testing for safety, efficacy, or sterility as branded products.

Quality Considerations

Not all compounding pharmacies maintain the same standards. Patients should verify that their pharmacy holds current Missouri Board of Pharmacy licensure, follows USP 797 sterile compounding guidelines, and provides certificates of analysis for each batch. The FDA's adverse event reporting system (MedWatch) has received reports of dosing errors and sterility concerns with compounded GLP-1 receptor agonists. Choosing a pharmacy that voluntarily submits to third-party accreditation (such as PCAB) reduces risk.

Compounded vs. Brand: Clinical Differences

Brand-name Wegovy uses Novo Nordisk's proprietary autoinjector pen with pre-set doses. Compounded semaglutide is typically dispensed in multi-dose vials requiring manual syringe drawing. This introduces the possibility of dosing variability. The 16-week titration schedule (0.25 mg weeks 1 to 4, 0.5 mg weeks 5 to 8, 1 mg weeks 9 to 12, 1.7 mg weeks 13 to 16, then 2.4 mg maintenance) should be followed regardless of the source, as the STEP-1 protocol used this schedule to minimize gastrointestinal side effects [1].

Telehealth Prescribing in Missouri

Missouri permits telehealth prescribing of Wegovy. A licensed prescriber can evaluate a patient via video or audio visit and issue a prescription that any Missouri pharmacy can fill.

How Telehealth Pricing Works

Telehealth platforms that prescribe Wegovy in Missouri charge a consultation fee ($50 to $199 for the initial visit) separate from the medication cost. Some platforms bundle the consultation with compounded semaglutide at a combined price of $249 to $399 per month. The prescriber must hold a valid Missouri medical license or practice under a multistate compact arrangement.

Prescribing Standards

The same clinical criteria apply regardless of visit modality. Missouri telehealth regulations require that the prescriber establish a valid patient-provider relationship, document the medical history, and confirm that the patient meets FDA-labeled indications for Wegovy. The American Telemedicine Association recommends that prescribers verify BMI through patient-reported height and weight, with follow-up in-person measurement when feasible.

How Wegovy Performs: Key Trial Data

The clinical evidence for semaglutide 2.4 mg rests on the STEP trial program and the SELECT cardiovascular outcomes trial.

STEP-1 Results

In STEP-1 (N=1,961), adults without diabetes receiving semaglutide 2.4 mg lost a mean of 14.9% of body weight over 68 weeks, compared to 2.4% with placebo. The most common adverse events were gastrointestinal: nausea (44.2%), diarrhea (31.5%), and vomiting (24.8%). Most GI events were mild to moderate and occurred during dose escalation [1].

STEP-2 in Type 2 Diabetes

STEP-2 (N=1,210) studied semaglutide 2.4 mg in adults with type 2 diabetes and overweight or obesity. Mean weight loss was 9.6% at 68 weeks versus 3.4% with placebo. HbA1c dropped by 1.6 percentage points with semaglutide versus 0.4 points with placebo [3].

SELECT Cardiovascular Outcomes

The SELECT trial (N=17,604) enrolled adults with established cardiovascular disease and BMI ≥27 without diabetes. Semaglutide 2.4 mg reduced the composite endpoint of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 20% over a median follow-up of 39.8 months (HR 0.80, 95% CI 0.72 to 0.90, P<0.001) [4].

Dr. Donna Ryan, associate editor of Obesity journal, noted in her editorial review: "SELECT changes the treatment approach. For the first time, a weight-management drug has demonstrated cardiovascular mortality benefit."

The 2024 AHA/ACC guidelines now include GLP-1 receptor agonists as a Class IIa recommendation for cardiovascular risk reduction in patients with obesity and established atherosclerotic disease.

Missouri-Specific Savings Strategies

Several approaches can reduce the cost of semaglutide therapy for Missouri patients beyond the manufacturer card and compounding options.

Patient Assistance Programs

Novo Nordisk's patient assistance program provides brand-name Wegovy at no cost to uninsured patients who meet income thresholds (typically <400% of the federal poverty level). Application requires income documentation and a signed prescription. Processing takes 4 to 6 weeks.

Pharmacy Discount Programs

Retail pharmacy discount cards (GoodRx, RxSaver, SingleCare) occasionally offer Wegovy pricing below WAC, though discounts on brand-name GLP-1 agonists remain limited. These cards provide more significant savings on compounded formulations. Independent Missouri pharmacies sometimes negotiate pricing directly with patients paying cash.

Employer Wellness Programs

Large Missouri employers (Cerner/Oracle Health, Bayer US, BJC HealthCare) have begun adding anti-obesity medications to their formularies as part of workplace wellness initiatives. The American Medical Association's policy statement on obesity treatment recognizes obesity as a chronic disease requiring pharmacologic and surgical options, which has increased employer willingness to cover these medications.

Side Effects and Monitoring

Patients starting Wegovy should expect gastrointestinal side effects during the titration phase. The prescribing information lists nausea, diarrhea, vomiting, constipation, and abdominal pain as the most common adverse reactions.

Required Monitoring

Prescribers should check baseline and periodic labs including fasting glucose, HbA1c, lipid panel, and renal function. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use semaglutide, per the boxed warning. Gallbladder-related events occurred in 2.6% of semaglutide patients versus 1.2% on placebo in STEP-1 [1].

When to Contact a Prescriber

Persistent vomiting lasting more than 48 hours, severe abdominal pain radiating to the back (possible pancreatitis), or signs of allergic reaction (facial swelling, difficulty breathing) require immediate medical evaluation. Missouri patients using telehealth should confirm they have a local emergency plan and know which urgent care or ER to visit.

The Wegovy maintenance dose of 2.4 mg once weekly should be reached by week 17 of treatment; patients unable to tolerate the escalation schedule may benefit from extending the titration, as the STEP-1 protocol permitted dose delays of up to 4 weeks at any step [1].